Acurx Pharmaceuticals
ACXP
24 hedge funds and large institutions have $1.36M invested in Acurx Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 7 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
18% more capital invested
Capital invested by funds: $1.15M → $1.36M (+$212K)
0.37% more ownership
Funds ownership: 0.42% → 0.79% (+0.37%)
8% less funds holding
Funds holding: 26 → 24 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.38M |
| 2 |
VCWA
Vanguard Capital Wealth Advisors
Denver,
Colorado
|
+$45.5K |
| 3 |
PFS
Prospect Financial Services
Melville,
New York
|
+$25.3K |
| 4 |
NS
NBC Securities
Birmingham,
Alabama
|
+$20.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$39.4K |
| 2 |
VF
Virtu Financial
New York
|
-$23K |
| 3 |
AA
ACT Advisors
Asheville,
North Carolina
|
-$17.3K |
| 4 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$14.9K |
| 5 |
Squarepoint
New York
|
-$10.2K |
ACXP Hedge Fund Activity: Q1 2025 in Review
24 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q1 2025, worth a combined $1.36M — up 18% from $1.15M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ACXP and 5 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.38M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $39.4K sold.
- 24 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q1 2025, down from 26 in Q4 2024.
- Funds reported $1.36M of Acurx Pharmaceuticals stock for Q1 2025, up 18% quarter-over-quarter.
- 5 funds opened new Acurx Pharmaceuticals positions in Q1 2025 and 7 closed out, a net change of -2 holders.
- The largest Acurx Pharmaceuticals buyer in Q1 2025 was Sabby Management, an estimated $1.38M added.
- The largest Acurx Pharmaceuticals seller in Q1 2025 was Susquehanna International Group, an estimated $39.4K sold.
Based on aggregated 13F filings for Q1 2025.